Cardiorenal syndrome type 2 (CRS2) is defined as a chronic cardiovascular disease, usually chronic heart failure (CHF), resulting in chronic kidney disease. We hypothesized that the cardiac spinal afferent reflex (CSAR) plays a critical role in the development of CRS2. Our data suggest that cardiac afferent ablation by resiniferatoxin not only improves cardiac function but also benefits the kidneys and increases long-term survival in the myocardial infarction model of CHF. We also found that renal denervation has a similar reno-protective effect in CHF rats. We believe this novel work contributes to the development of a unique neuromodulation therapy to treat CHF patients.
Keywords: BUN, blood urea nitrogen; CHF, chronic heart failure; CRS2, cardiorenal syndrome type 2; CSAR, cardiac spinal afferent reflex; EF, ejection fraction; FS, fractional shortening; GFR, glomerular filtration rate; HR, heart rate; Kim-1, kidney injury molecule 1; MAP, mean arterial blood pressure; MI, myocardial infarction; Ngal, neutrophil gelatinase–associated lipocalin; RBF, renal blood flow; RTX, resiniferatoxin; RVR, renal vascular resistance; URDN, unilateral renal denervation; cardiorenal syndrome type 2; cardiovascular reflexes; chronic heart failure; inflammation; renal failure; sympathoexcitation.
© 2022 The Authors.